At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE
In Brief
A Phase 2 clinical trial evaluating secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, and 1 other intervention for Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris. Completed, enrolled 111 participants across 35 sites in 3 countries.
Detailed Summary
The primary purpose of the proof of concept study is to elucidate the efficacy of secukinumab in the treatment of adult patients with biopsy-proven lichen planus not adequately controlled by topical therapies, and to assess the safety and tolerability over 32 weeks.
Study Details
Timeline
Interventions
secukinumab 300 mg administered every four weeks (Q4W) via a pre-filled syringe.
secukinumab 300 mg administered every two weeks (Q2W) via a pre-filled syringe.
Matching placebo administered via a pre-filled syringe